Background. Although gatifloxacin is no longer available, other fluoroquinolones may significantly interfere with glucose homeostasis. The objective of the present study was to compare the risk of severe hypo-and hyperglycemia in a cohort of patients treated with gatifloxacin, levofloxacin, ciprofloxacin, or azithromycin.
The fluoroquinolone antibiotics are widely used because they are generally well tolerated and have a broad spectrum of activity. However, gatifloxacin-which had been used in the treatment of a variety of infections, including those involving the skin and the respiratory and genitourinary tracts [1, 2] -was withdrawn from the market because of concerns about severe glucose disturbances. Although hypoglycemia and hyperglycemia were reported only rarely during clinical trials with gatifloxacin, severe dysglycemic events, typically in elderly patients and in patients with diabetes, were re-ported during the postmarketing period [3] and published in the medical literature [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
There have also been reports of glucose disturbances with other fluoroquinolones; therefore, it may be prudent to use them with caution as well in patients who are prone to hypo-and hyperglycemic events, such as individuals with diabetes [12, 15, 20, [22] [23] [24] [25] [26] . If dysglycemia was problematic with the other fluoroquinolones, one might suspect that there should be more reports with ciprofloxacin and levofloxacin, given that they were approved by the US Food and Drug Administration in 1987 and 1996, respectively. However, spontaneous reporting of adverse drug reactions tends to occur more frequently with newer medications, such as gatifloxacin [27] . Considering these factors, it is difficult to compare the incidence of dysglycemic events among the individual fluoroquinolones. The objective of the present study was to compare the risk of severe hypo-and hyperglycemia in a cohort of patients treated with gatifloxacin, ciprofloxacin, or levofloxacin or with a nonfluoroquinolone antibiotic, azithromycin. 
METHODS
Study design and sample selection. The institutional review boards at the Veterans Affairs (VA) Pittsburgh Healthcare System and the Edward Hines, Jr., VA Hospital/North Chicago VA Medical Center approved the study. VA outpatients with a prescription for gatifloxacin, levofloxacin, ciprofloxacin, or azithromycin from 1 October 2000 through 30 September 2005 were included. Data were examined using 2 general approaches, a descriptive surveillance method and a standard analytic method.
Our surveillance approach estimated the rates of severe hypoand hyperglycemia during the risk period of the drug (ie, within 15 days after the prescription date) by summing the number of unique patients with events in a calendar-year quarter and dividing by the number of unique patients filling an outpatient prescription for the drug in the quarter. This was repeated over time. This estimate is very simple, can be applied readily to the entire VA population, and can be used to visualize the pattern over time (figures 1 and 2). However, it is purely descriptive and does not take into account a variety of potential biases that may influence the patterns. A standard analytic approach using a retrospective inception (new users) cohort was employed to assess possible biases and characterize the potential association between fluoroquinolone use and dysglycemia. In the analytic approach, patients were included only once during the study period. We excluded patients if they received one of the study antibiotics within 24 weeks before the index date (ie, the date of the first antibiotic prescription during the study period), to ensure that only patients receiving new prescriptions were subjects. We also excluded patients with a primary inpatient diagnosis of hyperglycemia or hypoglycemia within 90 days of the index date so as to study only new-onset dysglycemic events. Finally, patients who received a single dose of the study antibiotics, were changed to another study antibiotic during the risk period, or did not have an age recorded were excluded from the cohort.
Data sources. Study data for all subjects came from the electronic administrative databases in the Department of Veterans Affairs medical care system. The VA national patient files maintained at the Austin Information Technology Center in Austin, Texas, provided information on all VA medical encounters, including outpatient clinic visits; inpatient admis- 3) during the risk period (ie, within 15 days after the prescription date). The following potential confounding factors were recorded: age at index date; presence or absence of preexisting diabetes (defined by use of antidiabetic drugs or ICD-9-CM codes 250.xx); chronic renal failure (ICD-9-CM codes 585 and 586); chronic liver disease, including alcohol-related disease (ICD-9-CM code 571); systemic malignancy (ICD-9-CM codes 140-208); and thiazide diuretic and corticosteroid use during the study period.
Analysis plan. All analyses were conducted using SAS, version 9.2 (SAS Institute). Cohort samples were characterized and compared in terms of demographics and other study variables. Odds ratios (ORs) comparing the fluoroquinolones to azithromycin were initially examined using stratified analyses. This was followed by multivariable logistic regression models to evaluate several possible confounders. The results are presented with a focus on estimation (ie, routine inclusion of 95% confidence intervals [CIs] ), but we indicate in the text where P values for ORs are !.05 (significant) or у.05 (not significant).
RESULTS

Descriptive results.
The estimates of event rates over time are shown in figures 1 (hypoglycemia) and 2 (hyperglycemia). The rates of events associated with gatifloxacin use were consistently above the rates seen with azithromycin, whereas levofloxacin showed a more variable pattern. These potential associations were further examined analytically using an inception cohort.
Analytic results. There were 1,352,793 outpatients with prescriptions for one of the study antibiotics. Patients receiving a study antibiotic within 24 weeks before the index date or who were hospitalized within 90 days before the index date were excluded. In addition, we also excluded patients who received a single dose, switched to another antibiotic, or had no age information. The final cohort included 874,682 patients with prescriptions for the fluoroquinolones and 402,566 pa-tients with prescriptions for azithromycin who met the inclusion and exclusion criteria (figure 3). Table 1 summarizes the characteristics of the individual cohorts and shows that subjects within each cohort were broadly similar with respect to age, sex, and potential confounding factors for hypo-and/or hyperglycemia.
The crude event rates for severe hypo-and hyperglycemia in the individual cohorts are presented in table 2. The estimated incidence of hypo-and hyperglycemia requiring hospitalization was greater with gatifloxacin and levofloxacin, but not ciprofloxacin, than with azithromycin. In addition, the incidence of hypo-and hyperglycemia was greater with gatifloxacin than with the other fluoroquinolones ( ). P ! .001 Table 3 shows the ORs for hypo-and hyperglycemia with each of the fluoroquinolones compared with azithromycin among patients with diabetes and among those without diabetes. Among the patients with diabetes, the odds of hypo-and hyperglycemia were significantly higher with gatifloxacin and levofloxacin than with azithromycin. The ORs among the nondiabetes population were not significant for any of the antibiotics. There was an insufficient number of events among patients without diabetes to reliably assess an interaction between diabetes status and the antibiotics (12 hypoglycemic and 39 hyperglycemic events) [28] . Given the low power and risk estimates, we focused the remainder of the analysis on patients with diabetes.
Although the antibiotic groups did not differ markedly with respect to a variety of baseline factors (or the prevalence was low), these factors (eg, age, chronic renal failure, malignancy, and corticosteroid use) were assessed in the logistic model for possible confounding. However, none changed the estimate of the OR by 110% (the "change-in-estimate" criterion) [29] . Therefore, we present the results of the simple, unadjusted model. In evaluating risks within the class of fluoroquinolones, the risk of hypo-and hyperglycemia with gatifloxacin was found to be significantly greater than with levofloxacin and ciprofloxacin in the population of patients with diabetes ( ). P ! .001
DISCUSSION
In May 2006, gatifloxacin was voluntarily withdrawn from the market because of concerns about severe hypo-and hyperglycemic events. Our results indicate that the incidence of severe dysglycemia requiring hospitalization is relatively low with all of the fluoroquinolones; however, it is still significantly greater for gatifloxacin and levofloxacin than for the nonfluoroquinolone antibiotic azithromycin. In addition, the odds of both hypo-and hyperglycemia were significantly greater with gatifloxacin than with levofloxacin and ciprofloxacin. Although gatifloxacin is no longer available, we remain concerned that levofloxacin still confers a significant risk for hypo-and hyperglycemia.
The effect of the fluoroquinolones on insulin secretion has been studied, and the results suggest that these antibiotics cause hypoglycemia by increasing insulin release via blockade of adenosine triphosphate-sensitive K + channels in the b cells of the pancreas [30, 31] . This effect may not be clinically significant in all patients because of physiologic mechanisms that regulate blood glucose levels. In contrast, the mechanism of hyperglycemia is not clear. One contributing factor may be overexposure (eg, failure to adjust the dose in patients with renal insufficiency) [32] . The results of our study and of others [12, 15, 16, 20, 21] , as well as this potentially common mechanism for hypoglycemia, suggest the need for caution when using certain fluoroquinolones, because the odds of hypo-and hyperglycemia appear to vary among the agents [33] . This is not unusual; differences in risk have been reported for other adverse effects with this class of antibiotics [34] .
Our results are generally consistent with those presented in the literature. In a retrospective medical-record review of dysglycemia in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone, dysglycemic events were more likely to occur in patients receiving gatifloxacin (relative risk, 3.29; 95% CI, 2.33-4.65) or levofloxacin (relative risk, 1.55; 95% CI, 1.29-1.88) versus ceftriaxone [20] . There was no difference in the risk of dysglycemia between gatifloxacin and levofloxacin ( ). However, hypo-and hyperglycemic P p .8 events were combined in this study. None of the patients who received ciprofloxacin experienced a dysglycemic event. In a nested case-control study of hospitalized patients who received gatifloxacin or levofloxacin, the odds of hypoglycemia were greater with gatifloxacin versus levofloxacin (OR, 2.81; 95% CI, 1.02-7.70) [12] . No comparator antibiotic was included in the study, so the possibility of a fluoroquinolone class effect could not be assessed. In another study of elderly inpatients who received gatifloxacin or levofloxacin, gatifloxacin was independently associated with hypoglycemia (OR, 2.4; 95% CI, 1.1-5.6) and hyperglycemia (OR, 2.5; 95% CI, 1.6-3.9) versus levofloxacin [21] . Again, a nonfluoroquinolone antibiotic was not included in the study.
Dysglycemic events have also been evaluated among outpatients receiving fluoroquinolones. In a smaller, regional database review of the effect of fluoroquinolones on glucose metabolism among veterans with an outpatient or discharge prescription for any of these antibiotics, Coblio et al [15] state that gatifloxacin was no more likely to cause hypo-or hyperglycemia than levofloxacin or ciprofloxacin among patients with or without diabetes, but they did not report statistical significance. In addition, no comparator was included, so the possibility of a class effect could not be assessed. In a nested case-control study of outpatient fluoroquinolone therapy and dysglycemia requiring hospitalization, gatifloxacin (OR, 4.3; 95% CI, 2.9-6.3) and levofloxacin (OR, 1.5; 95% CI, 1.2-2.0) were associated with an increased risk of hypoglycemia versus macrolides, but ciprofloxacin and moxifloxacin were not [16] . Compared with macrolide antibiotics, only gatifloxacin was associated with an increased risk of hyperglycemia (OR, 16.7; 95% CI, 10.4-26.8). The authors' findings were similar when their results were stratified by the presence or absence of diabetes. In our study, the small number of events in patients without diabetes (despite our large sample) combined with low ORs and lack of statistical significance suggest that clinical focus regarding risk with the remaining fluoroquinolones should be on those with diabetes.
Our study adds to the understanding of dysglycemia with fluoroquinolones in several ways. An important strength of our study is that it was conducted using a large population-based database. In addition, the analytic approach provided evidence for an association between specific fluoroquinolones-namely, gatifloxacin and levofloxacin-and hypo-and hyperglycemia. Although the selection criteria increase internal validity, the cost to external validity is not known. Our descriptive approach was complimentary in that it did not involve restricting the study population, thus speaking to generalizability. The similarity of the findings in our 2 approaches suggests that there is an association with certain fluoroquinolones and that it is not confined to a highly selected subset of the population.
However, there are limitations. Because our results were obtained using an administrative database, there are potential problems with coding of events and missing data. Missing data and miscoding should be random across antibiotics and the events were the primary diagnoses during hospitalization, but we did not validate these administrative diagnoses of hypo-and hyperglycemia with medical-record review and laboratory data. Although all of the events were severe enough to require hospitalization, we do not know the degree or duration of dysglycemia; therefore, it is possible that gatifloxacin was associated with more profound hypo-and/or hyperglycemia. We also captured data only from VA sources; therefore, we missed hospitalizations that occurred outside of VA medical centers. However, although this could explain the relatively low incidence of dysglycemic events found in our study, it is unlikely that there was a systematic difference in underascertainment of cases, so the association between the fluoroquinolones gatifloxacin and levofloxacin and the occurrence of hypo-and hyperglycemia is likely to remain significant. Given the nature of the database, we were unable to control for the indication for antibiotic use, and it is possible that certain infections are more likely to cause disturbances in the blood glucose. Also, the patients who received fluoroquinolones may have been sicker and more prone to dysglycemic events. Although we did not control for severity of illness or antibiotic indication, we did evaluate other variables, and none affected the strength of the association between the fluoroquinolones and the outcomes. Finally, moxifloxacin was not evaluated because its use in the system was negligible at the time of this study.
In conclusion, we have shown in a large, national cohort study that the risk of hypo-and hyperglycemia was greater with gatifloxacin and levofloxacin, but not ciprofloxacin, than with azithromycin. Additionally, the risk of severe hypo-and hyperglycemia was greater with gatifloxacin than with the other fluoroquinolones. Thus, the risk of a clinically relevant dysglycemic event appears to vary among the antibiotics in this class. We believe that clinicians should remain vigilant when prescribing fluoroquinolones, especially for patients who are prone to dysglycemic events. More research is needed on additional factors that may increase the risk of hypo-and hyperglycemia among patients receiving fluoroquinolones.
